Halozyme Therapeutics, Inc.
HALO
Revenue
290.08M
▲58.73M▲25.39%
3 Months ChangeAssets
2.12B
▲148.58M▲7.54%
3 Months ChangeLiabilities
1.67B
▼-14.70M▼-0.8751%
3 Months ChangeFree Cash Flow
125.88M
▲50.30M▲66.54%
12 Months ChangeRevenue/Cost Of Revenue
Revenue
Cost Of Revenue
Loading...
| Date | Revenue | Cost Of Revenue |
|---|---|---|
Net Profit/Loss
Net Profit/Loss
Baseline
Loading...
| Date | Net Profit/Loss |
|---|---|
Assets/Liabilities
Assets
Liabilities
Loading...
| Date | Assets | Liabilities |
|---|---|---|
Cash Flows
Operating (Cash Flow)
Investing (Cash Flow)
Financing (Cash Flow)
Free Cash Flow
Loading...
| Date | Operating (Cash Flow) | Investing (Cash Flow) | Financing (Cash Flow) | Free Cash Flow |
|---|---|---|---|---|
EPS
EPS (Diluted)
Loading...
| Date | EPS | EPS (Diluted) |
|---|---|---|
Outstanding Shares
Loading...
| Date | Outstanding Shares |
|---|---|
Recent 8-K/10-Q Filings
2024-10-31
Form 10-Q
ID: 0001159036-24-000050
2024-10-31
Form 8-K
ID: 0001159036-24-000049
2024-08-06
Form 10-Q
ID: 0001159036-24-000044
2024-08-06
Form 8-K
ID: 0001159036-24-000043
2024-05-07
Form 10-Q
ID: 0001159036-24-000037
2024-05-07
Form 8-K
ID: 0001159036-24-000036
2024-04-26
Form 8-K
ID: 0001159036-24-000031
2024-02-20
Form 8-K
ID: 0001159036-24-000007
2024-01-17
Form 8-K
ID: 0001159036-24-000003
2023-11-06
Form 10-Q
ID: 0001159036-23-000057